From Breakthrough to Bedside: Why Facilities Matter in CAR‑T Access

• CAR‑T is a clinical success. Access is the challenge.
• In CAR‑T manufacturing, the facility is not just a GMP container
• Facilities are silent enablers. Engineering decisions directly affect CAR-T outcomes.

Speakers:

Jordi Gibert

Head of Biotechnology Unit

Klinea Biotech & Pharma Engineering